Navigation Links
Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Date:11/10/2008

seases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial. In September 2008, Medivation entered into a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. For more information, please visit us at http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding future clinical development plans and milestones, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Medivation's actual results to differ significantly from those projected, including, without limitation, risks related to progress, timing and results of Medivation's clinical trials, difficulties or delays in obtaining regulatory approval, enrollment of patients in Medivation's clinical trials, partnering of Medivation's product candidates, manufacturing of Medivation's product candidates, competition with Medivation's product candidates should they receive marketing approval, the adequacy of Medivation's financial resources, unanticipated expenditures or liabilities, intellectual property matters, and other risks detailed in Medivation's filings with the Securities and Exchange Commissi
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
2. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
3. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
4. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
5. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
6. Medivation Announces Participation in Upcoming Conferences
7. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
8. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
9. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
10. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
11. Medivation Announces Senior Management Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014 Today the National Institutes ... grants for the Brain Research through Advancing Innovative ... develop and revolutionize new methods of understanding the ... brain. This first round of grants totaling $46 ... allocated to more than 100 investigators in 15 ...
(Date:10/1/2014)... Francisco, California (PRWEB) October 01, 2014 ... from the National Science Foundation to expand their bioCAD/CAM ... to build and modify DNA. The Small Business Innovation ... commercialize the “j5” technology under exclusive license from the ... Joint BioEnergy Institute , an LBNL laboratory that ...
(Date:9/30/2014)... D.C., September 30, 2014 Applying a well-known ... researchers at Harvard University has demonstrated the ability ... -- work that holds promise for making future, ... detailing the sides of next-gen rocket ships and ... light passes through oil in water, it becomes ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Shimadzu ... extensometer, an easy-to-use and highly precise tool for ... with considerable elongation. With 1000-mm maximum movement distance, ... percent for a gauge length of 10 mm. ... measurement accuracy above 50-mm stroke and within +/- ...
Breaking Biology Technology:NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 3TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Taking thin films to the extreme 2Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2
... UBS Global Life Sciences ... Conference, ... technology that accelerates the development,of life science and pharmaceutical products, today announced ... a top global,healthcare investment firm. MPM Capital also participated as a new ...
... 23 Arisyn Therapeutics Inc.,(Arisyn) announced today day ... Research, L.L.C. (UTR) a series of highly novel ... a variety of infectious organisms and cancer. Under ... intellectual property portfolio. In,return, UTR will receive a ...
... Global Certified Advantage Partnership streamlines management of patient ... data collected during ... Computer,Services Ltd. (NYSE: SAY ), a leading global ... working with Oracle,s,new Health Sciences Global Business Unit to ...
Cached Biology Technology:ForteBio, Inc. Closes $25 Million In Series C Financing 2ForteBio, Inc. Closes $25 Million In Series C Financing 3Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer 2Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer 3Satyam Partners with Oracle to Provide Clinical Development Applications 2Satyam Partners with Oracle to Provide Clinical Development Applications 3Satyam Partners with Oracle to Provide Clinical Development Applications 4
(Date:9/30/2014)... tourists visit the Mediterranean each year, but its ... on Earth. Almost 1,000 alien species, including fish, ... seas through human activities. In the open-access journal ... team of researchers analyzed data from a new ... show how the introduction of alien species has ...
(Date:9/30/2014)... San Diego, have completed the first comprehensive numerical simulation ... the pixels in an image as data points for ... The researchers, led by J.S. Chen, the William Prager ... Engineering at UC San Diego, presented their findings on ... in Pittsburgh this month. Chen also gave a keynote ...
(Date:9/30/2014)... by the Ocean Health Index rates the Earth,s ... health. In addition, for the first time, the ... regions beyond national jurisdiction (high-seas areas) all ... biodiversity and providing sustainable food sources. , In ... partnership led by scientists from UC Santa Barbara,s ...
Breaking Biology News(10 mins):Biodiversity in the Mediterranean is threatened by alien species 2First comprehensive meshfree numerical simulation of skeletal muscle tissue achieved 2Rating the planet's oceans 2Rating the planet's oceans 3
... Since Moffat and Ramsden for the first time discovered ... 1977, over the last two decades, great progress has ... Jrgensen and Mathiesen were the first authors to note ... in adult Australian parrots. Later, Roberson et al studied ...
...  DiscoveRx Corporation, through its BioSeek division, today announced ... assay platform for oncology research. Consisting of primary ... panel enables researchers to easily assess the phenotypic ... to better predict in vivo drug ...
... plants, the growth of organs such as roots, leaves ... reservoir-like compartments hold stem cells, which have the ability ... At Cold Spring Harbor Laboratory (CSHL), Professor David ... insights about how plants regulate their growth. This work ...
Cached Biology News:DiscoveRx Announces Launch of New Human Primary Cell-Based Panels for Oncology Research 2DiscoveRx Announces Launch of New Human Primary Cell-Based Panels for Oncology Research 3In odd-looking mutant, clues about how maize plants control stem cell number 2
...
...
... Comments: Ab-1 stains tumor cells of embryonal ... type of germ cell tumors like seminoma. Glandular ... are positive. Luminal and endocrine cells of stomach ... breast are also positive. Epitope: Carbohydrate ...
TP-1 (NDOG1)...
Biology Products: